Skip Ribbon Commands
Skip to main content

Dr Tan Jing Ying Tira

Dr Tan Jing Ying Tira



National Cancer Centre Singapore

Specialty: Medical Oncology

Sub-specialties: Breast

Conditions Treated by this Doctor:
Breast Cancer .

Clinical Appointments

  • Consultant Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore

Academic Appointments

  • Clinical Lecturer at NUS Yong Loo Lin School of Medicine
  • Clinical Instructor at Duke-NUS Medical School


Dr Tira Tan's research interest is in the study of breast cancer and geriatric oncology. In particular, her focus is on triple negative breast cancer and the conduct of early phase clinical trials. Her academic training and clinical experience has provided her with a broad and solid foundation in medical oncology. Through her training, she has actively participated in research. In the field of geriatric oncology, her abstract on Malnutrition in Elderly Asian Cancer Patients submitted to the American Society of Oncology meeting in 2013 was award with a merit award. Following the completion of her training in October 2015, she joined the Breast team as well as the Phase 1 unit where she actively recruits and follow up on patients in several clinical trials for which she is a co-investigator. She has conceptualized and written several investigator-initiated protocols one of which has started actively recruiting patients. 

With a growing practice and accumulating experience in the treatment of triple negative breast cancers, she recognise that this represents an area in need for further research and drug development. In addition, Dr Tira Tan strongly believe in improving drug efficacy, toxicity profile and an individualized approach to cancer treatment through established and well-validated companion biomarkers.


  • MBBS, Imperial College of Science, Technology & Medicine, University of London 
  • BSc, Imperial College of Science, Technology & Medicine, University of London 

Professional Appointments and Committee Memberships


Research Interests


  • Yee MS, Pavitt DV, Tan T, Venkatesan S, Godsland IF, Richmond W, Johnston DG. Lipoprotein separation in a novel iodixanol density gradient, for composition, density, and phenotype analysis. J Lipid Res. 2008 Jun;49(6):1364-71. doi: 10.1194/jlr.D700044-JLR200. Epub 2008 Mar 12. 
  • Wang YT, Lim HY, Tai D, Krishnamoorthy TL, Tan T, Barbier S, Thumboo J. The impact of irritable bowel syndrome on health-related quality of life: a Singapore perspective. BMC Gastroenterol. 2012 Aug 9;12:104. doi: 10.1186/1471-230X-12-104. 
  • Jain A, Tan TJ, Tan DS. Carcinoma of unknown primary site. N Engl J Med. 2014 Nov 20;371(21):2039. doi: 10.1056/NEJMc1411384#SA1. No abstract available. 
  • Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer. Singapore Cancer Network (SCAN) Lung Cancer Workgroup. Ann Acad Med Singapore. 2015 Oct;44(10):449-62 
  • Rajasekaran T, Tan T, Ong WS, Koo KN, Chan L, Poon D, Roy Chowdhury A, Krishna L, Kanesvaran. Comprehensive Geriatric Assessment (CGA) based risk factors for increased caregiver burden among elderly Asian patients with cancer. J Geriatr Oncol. 2016 Apr 7. pii: S1879-4068(16)30021-2. doi: 10.1016/j.jgo.2016.03.003. [Epub ahead of print] 
  • Tan T, Ong WS, Rajasekaran T, Koo KN, Chan LL, Poon D, Chowdhury AR, Krishna L, Kanesvaran R. Identification of Comprehensive Geriatric Assessment Based Risk Factors for Malnutrition in Elderly Asian Cancer Patients. PloS one. 2016 May 27;11(5):e0156008. 

Research Trials

  • An open- label, single-arm phase 2 clinical trial of Regorafenib in patients with multiply recurrent epithelial ovarian cancer 
  • Prospective Phase Ib-II clinical trial to evaluate the safety and activity of Oregovomab and Nivolumab as a combinatorial immunotherapy strategy in patients with recurrent epithelial cancer of ovarian, tubal or Peritoneal Origin (ORION-01 / NCCOV-02)